Insulin to treat Alzheimer's disease: just follow your nose?

Insulin to treat Alzheimer's disease : just follow your nose?

Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes, and lower cerebrospinal insulin levels. Against this background, impaired brain insulin signaling may account for some of the cognitive deficits associated with this disease. Using the intranasal method, which effectively bypasses the blood-brain barrier to deliver and target insulin directly from the nose to the brain, a series of acute clinical trials involving healthy humans and AD patients have shown that increased CNS insulin action enhances learning and memory processes. This article summarizes and evaluates data from a recently published clinical trial, in which 4 months of intranasal insulin administration (20 IU insulin/day) preserved not only general cognition but also reduced the loss of metabolic integrity of the brain in adults with mild-to-moderate AD.

Frey, William H.HealthPartners Res Fdn, Alzheimers Res Ctr Reg Hosp, St Paul, MN USA (author)
Brooks, Samantha J.Uppsala universitet,Funktionell farmakologi(Swepub:uu)sambr210 (author)
Benedict, ChristianUppsala universitet,Funktionell farmakologi(Swepub:uu)chrbe136 (author)
Uppsala universitetFunktionell farmakologi (creator_code:org_t)

In:Expert Review of Clinical Pharmacology: Informa UK Limited5:1, s. 17-201751-24331751-2441

By the author/editor: Schiöth, Helgi B ...; Frey, William H.; Brooks, Samantha ...; Benedict, Christ ...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Pharmaceutical S ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.